Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
Phase of Trial: Phase I/II
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Cisplatin (Primary) ; Pembrolizumab (Primary) ; Rintatolimod (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 11 Feb 2019 According to a Hemispherx Biopharma media release, first subject has been enrolled in the trial.
- 11 Feb 2019 Status changed from not yet recruiting to recruiting, according to a Hemispherx Biopharma media release.
- 06 Dec 2018 Planned initiation date changed from 20 Nov 2018 to 31 Jan 2019.